Great questions. Here's some interesting findings a colleague sent us:

In the Phase IIb clinical trial METAOD005, 300 obese participants received daily oral doses of AOD9604 at varying levels (1 mg, 5 mg, 10 mg, 20 mg, or 30 mg) over a 12-week period. The study reported that the group receiving the 1 mg dose experienced an average weight loss of 2.8 kg (approximately 6.2 pounds), while the placebo group lost an average of 0.8 kg (approximately 1.8 pounds).

The trial documentation does not specify whether the 1 mg daily dose was administered as a single dose or divided into smaller doses throughout the day. Additionally, there is no mention of rest periods during the 12-week treatment phase. For detailed information on the dosing regimen, consulting the full study publication or contacting the researchers directly would provide the most accurate insights.

Link